[Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects].
Because of its severe side effects, initial clinical trials of the antineoplastic compound mitoguazone (Methyl-GAG, M-G) were ceased in the middle of 1960s. One decade later pharmacokinetically guided dose schedules as well as new experimental data on the antiproliferative mechanism of action stimulated new clinical studies. First results indicated that M-G had single-agent activity against various tumors such as acute leukemia and malignant lymphoma connected with acceptable tolerance. M-G seems to be effective especially in combination with other antineoplastic drugs. Its final evaluation may be reserved to further randomized trials. Recently, the psoriasis vulgaris is expected to be an additional field of the application of M-G. In this minireview data on synthesis, preclinical pharmacology, pharmacokinetics, biochemical effects and toxicology of M-G are given. Furthermore, clinical findings on M-G concerning its pharmacokinetic behaviour, antitumor and antipsoriatic activities are described.
Hoffmann
H
H
Zentralinstitut für Mikrobiologie und experimentelle Therapie, Jena.
Gutsche
W
W
Amlacher
R
R
Schulze
W
W
Werner
W
W
Lenk
H
H
Wohlrab
W
W
Haupt
E
E
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D006801:Humans; D007928:Lethal Dose 50; D008935:Mitoguazone / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy
D008935:Mitoguazone
Mitoguazon (Methylglyoxal-bis-guanylhydrazon)--Stand und Perspektiven.